Female gender and exogenous progesterone exposition as risk factors for spheno-orbital meningiomas.
Adult
Aged
Aged, 80 and over
Female
Follow-Up Studies
Humans
Male
Meningeal Neoplasms
/ etiology
Meningioma
/ etiology
Middle Aged
Orbital Diseases
/ etiology
Progesterone
/ adverse effects
Progestins
/ adverse effects
Prognosis
Retrospective Studies
Risk Factors
Sex Factors
Skull Neoplasms
/ etiology
Sphenoid Bone
/ pathology
Cyproterone acetate
Nomegestrol acetate
Osteomeningioma
Progestin
Skull base meningioma
Sphenoorbital meningioma
Journal
Journal of neuro-oncology
ISSN: 1573-7373
Titre abrégé: J Neurooncol
Pays: United States
ID NLM: 8309335
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
04
04
2020
accepted:
25
06
2020
pubmed:
25
7
2020
medline:
22
6
2021
entrez:
25
7
2020
Statut:
ppublish
Résumé
The great heterogeneity of meningiomas is challenging and we need to distinguish relevant subgroups. Spheno-orbital osteomeningiomas (SOOM) constitute a clinically specific entity, with slow-growing benign osteo-meningiomatous tumors, which recur after surgery in one fourth of cases. Neurosurgical daily practice, supported by the literature, shows that the vast majority of patients with SOOM are women, and we explored whether their epidemiological and hormonal profiles suggest a progesterone influence. We retrospectively documented all radiologically and histologically confirmed cases of SOOM operated in 2005-2019 in our institution. We completed the clinical and hormone history by systematic telephone interviews. In the literature, SOOM occur significantly more often in women than other meningiomas (749/847, 86.4% versus 73.8%, p = 0.002). Among 175 cases, we included 124 patients, 93.5% were women, younger than men (51 ± 5 versus 63 ± 8, p = 0.02). Women' meningiomas showed more progesterone receptors (96.4% versus 50%, p < 0.001). Exogenous hormonal intake, reliable in 82 cases, concerned 83.3% (64/78) of women, with frequent progesterone intake: 13 oestroprogestogenic treatment only, with old-generation progesterone analogs, 41 progesterone analogs (cyproterone acetate, nomegestrol acetate, chlormadinone, promegestone, etonogestrel, levonogestrel), 7 substitutive hormonal therapy for menopause, 3 others. Duration of treatment was 2-40 years, median 10 years. SOOM develop preferentially in women in their fifties, who often received progesterone analogs, and show progesterone receptors. Progesterone analogs are incriminated in skull base meningiomas, and this is the first report on the prevalence of exogenous hormone therapy specifically in SOOM. Whether SOOM reduce after treatment discontinuation, in particular the osteoma part, needs to be explored. Anti-progesterone treatments may represent an avenue for future research in soom.
Identifiants
pubmed: 32705456
doi: 10.1007/s11060-020-03576-8
pii: 10.1007/s11060-020-03576-8
doi:
Substances chimiques
Progestins
0
Progesterone
4G7DS2Q64Y
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
95-101Références
Youngblood MW, Duran D, Montejo JD et al (2019) Correlations between genomic subgroup and clinical features in a cohort of more than 3000 meningiomas. J Neurosurg. https://doi.org/10.3171/2019.8.JNS191266
doi: 10.3171/2019.8.JNS191266
pubmed: 31653806
Yuzawa S, Nishihara H, Tanaka S (2016) Genetic landscape of meningioma. Brain Tumor Pathol 33(4):237–247. https://doi.org/10.1007/s10014-016-0271-7
doi: 10.1007/s10014-016-0271-7
pubmed: 27624470
Bernat AL, Oyama K, Hamdi S et al (2015) Growth stabilization and regression of meningiomas after discontinuation of cyproterone acetate: a case series of 12 patients. Acta Neurochir (Wien) 157(10):1741–1746. https://doi.org/10.1007/s00701-015-2532-3
doi: 10.1007/s00701-015-2532-3
Harland TA, Freeman JL, Davern M et al (2018) Progesterone-only contraception is associated with a shorter progression-free survival in premenopausal women with WHO Grade I meningioma. J Neurooncol 136(2):327–333. https://doi.org/10.1007/s11060-017-2656-9
doi: 10.1007/s11060-017-2656-9
pubmed: 29081037
Peyre M, Gaillard S, de Marcellus C et al (2018) Progestin-associated shift of meningioma mutational landscape. Ann Oncol 29(3):681–686. https://doi.org/10.1093/annonc/mdx763
doi: 10.1093/annonc/mdx763
pubmed: 29206892
Terrier L-M, Bernard F, Fournier H-D et al (2018) Spheno-orbital meningiomas surgery: multicenter management study for complex extensive tumors. World Neurosurg 112:e145–e156. https://doi.org/10.1016/j.wneu.2017.12.182
doi: 10.1016/j.wneu.2017.12.182
pubmed: 29317363
Scarone P, Leclerq D, Héran F, Robert G (2009) Long-term results with exophthalmos in a surgical series of 30 sphenoorbital meningiomas. Clin J Neurosurg 111(5):1069–1077. https://doi.org/10.3171/2009.1.JNS081263
doi: 10.3171/2009.1.JNS081263
Dolecek TA, Propp JM, Stroup NE, Kruchko C (2012) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro-Oncology 15(5):646–647. https://doi.org/10.1093/neuonc/nos218
doi: 10.1093/neuonc/nos218
Vincelet C, Galli J, Grémy I (2006) Surpoids et obésité en Ile-de-France. Obs Régional Santé
Belinsky I, Murchison AP, Evans JJ et al (2018) Spheno-orbital meningiomas: an analysis based on World Health Organization Classification and Ki-67 Proliferative Index. Ophthal Plast Reconstr Surg 34(2):143–150. https://doi.org/10.1097/IOP.0000000000000904
doi: 10.1097/IOP.0000000000000904
pubmed: 28350689
Civit T, Freppel S (2010) Sphenoorbital meningiomas. Neurochirurgie 56(2–3):124–131. https://doi.org/10.1016/j.neuchi.2010.02.022
doi: 10.1016/j.neuchi.2010.02.022
pubmed: 20303557
Mariniello G, Bonavolontà G, Tranfa F, Maiuri F (2013) Management of the optic canal invasion and visual outcome in spheno-orbital meningiomas. Clin Neurol Neurosurg 115(9):1615–1620. https://doi.org/10.1016/j.clineuro.2013.02.012
doi: 10.1016/j.clineuro.2013.02.012
pubmed: 23477706
Nagatani K, Takeuchi S, Otani N, Nawashiro H (2011) Surgical management of spheno-orbital meningiomas. Acta Neurochir (Wien) 153(7):1541; author reply 1539–1540. https://doi.org/10.1007/s00701-011-1037-y
doi: 10.1007/s00701-011-1037-y
Peron S, Cividini A, Santi L, Galante N, Castelnuovo P, Locatelli D (2017) Spheno-orbital meningiomas: when the endoscopic approach is better. Acta Neurochir Suppl 124:123–128. https://doi.org/10.1007/978-3-319-39546-3_19
doi: 10.1007/978-3-319-39546-3_19
pubmed: 28120063
Shapey J, Jung J, Barkas K et al (2019) A single centre’s experience of managing spheno-orbital meningiomas: lessons for recurrent tumour surgery. Acta Neurochir (Wien) 161(8):1657–1667. https://doi.org/10.1007/s00701-019-03977-3
doi: 10.1007/s00701-019-03977-3
Spuler A (2010) Spheno-orbital meningiomas: how to follow up and for how long? HNO 58(1):35–36. https://doi.org/10.1007/s00106-009-2047-4
doi: 10.1007/s00106-009-2047-4
pubmed: 20076937
Saeed P, van Furth WR, Tanck M et al (2011) Surgical treatment of sphenoorbital meningiomas. Br J Ophthalmol 95(7):996–1000. https://doi.org/10.1136/bjo.2010.189050
doi: 10.1136/bjo.2010.189050
pubmed: 21242579
Saeed P, van Furth WR, Tanck M et al (2011) Natural history of spheno-orbital meningiomas. Acta Neurochir (Wien) 153(2):395–402. https://doi.org/10.1007/s00701-010-0878-0
doi: 10.1007/s00701-010-0878-0
Yannick N, Patrick F, Samuel M et al (2012) Predictive factors for visual outcome after resection of spheno-orbital meningiomas: a long-term review. Acta Ophthalmol (Copenh) 90(8):e663–e665. https://doi.org/10.1111/j.1755-3768-2012.02419.x
doi: 10.1111/j.1755-3768-2012.02419.x
Forster M-T, Daneshvar K, Senft C, Seifert V, Marquardt G (2014) Sphenoorbital meningiomas: surgical management and outcome. Neurol Res 36(8):695–700. https://doi.org/10.1179/1743132814Y.0000000329
doi: 10.1179/1743132814Y.0000000329
pubmed: 24620980
Freeman JL, Davern MS, Oushy S et al (2017) Spheno-orbital meningiomas: a 16-year surgical experience. World Neurosurg 99:369–380. https://doi.org/10.1016/j.wneu.2016.12.063
doi: 10.1016/j.wneu.2016.12.063
pubmed: 28017748
Gonen L, Nov E, Shimony N, Shofty B, Margalit N (2018) Sphenoorbital meningioma: surgical series and design of an intraoperative management algorithm. Neurosurg Rev 41(1):291–301. https://doi.org/10.1007/s10143-017-0855-7
doi: 10.1007/s10143-017-0855-7
pubmed: 28474186
Honig S, Trantakis C, Frerich B, Sterker I, Schober R, Meixensberger J (2010) Spheno-orbital meningiomas: outcome after microsurgical treatment: a clinical review of 30 cases. Neurol Res 32(3):314–325. https://doi.org/10.1179/016164109X12464612122614
doi: 10.1179/016164109X12464612122614
pubmed: 19726012
Kiyofuji S, Casabella AM, Graffeo CS, Perry A, Garrity JA, Link MJ (2019) Sphenoorbital meningioma: a unique skull base tumor. Surgical technique and results. J Neurosurg. https://doi.org/10.3171/2019.6.JNS191158
doi: 10.3171/2019.6.JNS191158
pubmed: 31443076
Leroy H-A, Leroy-Ciocanea CI, Baroncini M et al (2016) Internal and external spheno-orbital meningioma varieties: different outcomes and prognoses. Acta Neurochir (Wien) 158(8):1587–1596. https://doi.org/10.1007/s00701-016-2850-0
doi: 10.1007/s00701-016-2850-0
Maschke S, Martínez-Moreno M, Micko A et al (2019) Challenging the osseous component of sphenoorbital meningiomas. Acta Neurochir (Wien) 161(11):2241–2251. https://doi.org/10.1007/s00701-019-04015-y
doi: 10.1007/s00701-019-04015-y
Oya S, Sade B, Lee JH (2011) Sphenoorbital meningioma: surgical technique and outcome. J Neurosurg 114(5):1241–1249. https://doi.org/10.3171/2010.10.JNS101128
doi: 10.3171/2010.10.JNS101128
pubmed: 21184631
Schick U (2010) Sphenoorbital meningiomas: results in long-term treatment. HNO 58(1):37–43. https://doi.org/10.1007/s00106-009-2024-y
doi: 10.1007/s00106-009-2024-y
pubmed: 20011997
Solmaz I, Tehli O, Temiz C et al (2014) Surgical strategies for the removal of sphenoorbital meningiomas. Turk Neurosurg 24(6):859–866. https://doi.org/10.5137/1019-5149.JTN.10336-14.3
doi: 10.5137/1019-5149.JTN.10336-14.3
pubmed: 25448201
Terpolilli NA, Ueberschaer M, Niyazi M et al (2019) Long-term outcome in orbital meningiomas: progression-free survival after targeted resection combined with early or postponed postoperative radiotherapy. J Neurosurg. https://doi.org/10.3171/2019.3.JNS181760
doi: 10.3171/2019.3.JNS181760
pubmed: 31200373
Young J, Mdanat F, Dharmasena A et al (2019) Combined neurosurgical and orbital intervention for spheno-orbital meningiomas—the Manchester experience. Orbit Amst Neth. https://doi.org/10.1080/01676830.2019.1673782
doi: 10.1080/01676830.2019.1673782
Claus EB, Calvocoressi L, Bondy ML, Wrensch M, Wiemels JL, Schildkraut JM (2013) Exogenous hormone use, reproductive factors, and risk of intracranial meningioma in females. J Neurosurg 118(3):649–656. https://doi.org/10.3171/2012.9.JNS12811
doi: 10.3171/2012.9.JNS12811
pubmed: 23101448
Wigertz A, Lönn S, Mathiesen T, Ahlbom A, Hall P, Feychting M (2006) Risk of brain tumors associated with exposure to exogenous female sex hormones. Am J Epidemiol 164(7):629–636. https://doi.org/10.1093/aje/kwj254
doi: 10.1093/aje/kwj254
pubmed: 16835295
Piper JG, Follett KA, Fantin A (1994) Sphenoid wing meningioma progression after placement of a subcutaneous progesterone agonist contraceptive implant. Neurosurgery. https://doi.org/10.1227/00006123-199404000-00022
doi: 10.1227/00006123-199404000-00022
pubmed: 8008172
Carroll RS, Glowacka D, Dashner K, Black PM (1993) Progesterone receptor expression in meningiomas. Cancer Res 53(6):1312–1316
pubmed: 8443810
Passeri T, Champagne P-O, Bernat A-L et al (2019) Spontaneous regression of meningiomas after interruption of nomegestrol acetate: a series of three patients. Acta Neurochir (Wien) 161(4):761–765. https://doi.org/10.1007/s00701-019-03848-x
doi: 10.1007/s00701-019-03848-x
Champagne P-O, Passeri T, Froelich S (2019) Combined hormonal influence of cyproterone acetate and nomegestrol acetate on meningioma: a case report. Acta Neurochir (Wien) 161(3):589–592. https://doi.org/10.1007/s00701-018-03782-4
doi: 10.1007/s00701-018-03782-4
Bernat AL, Bonnin S, Labidi M et al (2018) Regression of giant olfactory groove meningioma and complete visual acuity recovery after discontinuation of cyproterone acetate. J Ophthalmic Vis Res 13(3):355–358. https://doi.org/10.4103/jovr.jovr_21_17
doi: 10.4103/jovr.jovr_21_17
pubmed: 30090195
Shahin MN, Magill ST, Dalle Ore CL et al (2019) Fertility treatment is associated with multiple meningiomas and younger age at diagnosis. J Neurooncol 143(1):137–144. https://doi.org/10.1007/s11060-019-03147-6
doi: 10.1007/s11060-019-03147-6
pubmed: 30868355
pmcid: 6486831
Donnell MS, Meyer GA, Donegan WL (1979) Estrogen-receptor protein in intracranial meningiomas. J Neurosurg 50(4):499–502. https://doi.org/10.3171/jns.1979.50.4.0499
doi: 10.3171/jns.1979.50.4.0499
pubmed: 423006
Korhonen K, Salminen T, Raitanen J, Auvinen A, Isola J, Haapasalo H (2006) Female predominance in meningiomas can not be explained by differences in progesterone, estrogen, or androgen receptor expression. J Neurooncol 80(1):1–7. https://doi.org/10.1007/s11060-006-9146-9
doi: 10.1007/s11060-006-9146-9
pubmed: 16703453
Hsu DW, Efird JT, Hedley-Whyte ET (1997) Progesterone and estrogen receptors in meningiomas: prognostic considerations. J Neurosurg 86(1):113–120. https://doi.org/10.3171/jns.1997.86.1.0113
doi: 10.3171/jns.1997.86.1.0113
pubmed: 8988089
Roser F, Nakamura M, Bellinzona M, Rosahl SK, Ostertag H, Samii M (2004) The prognostic value of progesterone receptor status in meningiomas. J Clin Pathol 57(10):1033–1037. https://doi.org/10.1136/jcp.2004.018333
doi: 10.1136/jcp.2004.018333
pubmed: 15452155
pmcid: 1770447
Ji Y, Rankin C, Grunberg S et al (2015) Double-blind phase III randomized trial of the antiprogestin agent mifepristone in the treatment of unresectable meningioma: SWOG S9005. J Clin Oncol Off J Am Soc Clin Oncol 33(34):4093–4098. https://doi.org/10.1200/JCO.2015.61.6490
doi: 10.1200/JCO.2015.61.6490
Sharma R, Garg K, Katiyar V et al (2019) The role of mifepristone in the management of meningiomas: a systematic review of literature. Neurol India 67(3):698–705. https://doi.org/10.4103/0028-3886.263232
doi: 10.4103/0028-3886.263232
pubmed: 31347538
Touat M, Lombardi G, Farina P, Kalamarides M, Sanson M (2014) Successful treatment of multiple intracranial meningiomas with the antiprogesterone receptor agent mifepristone (RU486). Acta Neurochir (Wien) 156(10):1831–1835. https://doi.org/10.1007/s00701-014-2188-4
doi: 10.1007/s00701-014-2188-4
Boetto J, Bielle F, Sanson M, Peyre M, Kalamarides M (2017) SMO mutation status defines a distinct and frequent molecular subgroup in olfactory groove meningiomas. Neuro-Oncology 19(3):345–351. https://doi.org/10.1093/neuonc/now276
doi: 10.1093/neuonc/now276
pubmed: 28082415
pmcid: 5464306